GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merrimack Pharmaceuticals Inc (NAS:MACK) » Definitions » Cyclically Adjusted Price-to-FCF

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Cyclically Adjusted Price-to-FCF : (As of Jun. 09, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Merrimack Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Merrimack Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Merrimack Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merrimack Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Merrimack Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Merrimack Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Merrimack Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Merrimack Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merrimack Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merrimack Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Merrimack Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Merrimack Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Merrimack Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Merrimack Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.091/131.7762*131.7762
=-0.091

Current CPI (Mar. 2024) = 131.7762.

Merrimack Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -3.312 100.560 -4.340
201409 5.661 100.428 7.428
201412 -3.112 99.070 -4.139
201503 -3.386 99.621 -4.479
201506 -2.499 100.684 -3.271
201509 -4.129 100.392 -5.420
201512 -0.612 99.792 -0.808
201603 -4.718 100.470 -6.188
201606 -4.100 101.688 -5.313
201609 -2.766 101.861 -3.578
201612 -2.362 101.863 -3.056
201703 -0.800 102.862 -1.025
201706 -4.924 103.349 -6.278
201709 -1.963 104.136 -2.484
201712 -1.873 104.011 -2.373
201803 -1.301 105.290 -1.628
201806 -1.225 106.317 -1.518
201809 -0.983 106.507 -1.216
201812 -1.416 105.998 -1.760
201903 -1.023 107.251 -1.257
201906 -0.890 108.070 -1.085
201909 -0.240 108.329 -0.292
201912 -0.197 108.420 -0.239
202003 -0.075 108.902 -0.091
202006 -0.148 108.767 -0.179
202009 0.010 109.815 0.012
202012 -0.133 109.897 -0.159
202103 -0.033 111.754 -0.039
202106 0.076 114.631 0.087
202109 -0.033 115.734 -0.038
202112 -0.026 117.630 -0.029
202203 -0.026 121.301 -0.028
202206 -0.070 125.017 -0.074
202209 -0.020 125.227 -0.021
202212 -0.013 125.222 -0.014
202303 -0.025 127.348 -0.026
202306 -0.047 128.729 -0.048
202309 -0.014 129.860 -0.014
202312 -0.021 129.419 -0.021
202403 -0.091 131.776 -0.091

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Merrimack Pharmaceuticals  (NAS:MACK) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Merrimack Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Merrimack Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
One Broadway, 14th Floor, Cambridge, MA, USA, 02142
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
Executives
Eric Andersen director, other: See Remarks 1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404
Gary L Crocker director, officer: President MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Noah G. Levy director, other: See Remarks 60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165
Ana Radeljevic director 2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467
Ulrik B. Nielsen director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Russell T Ray director 2525 DUPONT DR, IRVINE CA 92612
Newtyn Capital Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Ledo Capital, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Te Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Western Standard Partners Qp, L.p. other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Partners Lp other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Llc other: See Remarks 5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036
Newtyn Management, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
22nw Gp, Inc. 10 percent owner, other: See Explanation of Responses 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Headlines

From GuruFocus

Merrimack Reports First Quarter 2022 Financial Results

By Business Wire Business Wire 05-05-2022

Steven Cohen Buys 4, Sells 1 in 2nd Quarter

By GuruFocus Research GuruFocus Editor 08-15-2022

Merrimack Declares $20 Million Special Dividend

By PRNewswire PRNewswire 07-25-2019

Merrimack Reports Full Year 2021 Financial Results

By Business Wire Business Wire 03-09-2022

JFL Capital Issues Letter to Fellow Merrimack Stockholders

By PRNewswire PRNewswire 08-22-2019

Merrimack Reports Second Quarter 2022 Financial Results

By Business Wire Business Wire 08-04-2022